REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.

Nivolumab is an increasingly used standard care treatment for heavily pretreated patients with advanced gastric cancer, with increasing clinical use in Japan. Data from retrospective studies on various tumors have shown the objective response rate to cytotoxic chemotherapy potentially improves after an exposure to immune checkpoint inhibitors. Based on these data, we conducted the multicenter observational REVIVE study to evaluate the efficacy and safety of cytotoxic chemotherapy in nivolumab-refractory or nivolumab-intolerant patients with advanced gastric cancer. Patients who are refractory or intolerant to nivolumab and scheduled to receive irinotecan monotherapy, oxaliplatin combination treatment or oral trifluridine/tipiracil hydrochloride therapy will be included. The primary end point is overall survival of nivolumab-pretreated patients with advanced gastric cancer after the cytotoxic chemotherapy. Clinical trial registration: UMIN000032182.

[1]  C. Fuchs,et al.  O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma , 2020 .

[2]  K. Muro,et al.  Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer , 2020, AntiCancer Research.

[3]  N. Yamamoto,et al.  Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L) , 2020, Journal for ImmunoTherapy of Cancer.

[4]  F. Bidault,et al.  Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. , 2019, European journal of cancer.

[5]  G. Beretta,et al.  Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  E. Van Cutsem,et al.  Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Sean S. Park,et al.  CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. , 2018, JCI insight.

[9]  K. Muro,et al.  Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan , 2018, Gastric Cancer.

[10]  J. Ahn,et al.  Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  K. Akashi,et al.  Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer , 2018, Gastric Cancer.

[12]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[13]  J. Lee,et al.  Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. , 2017, Lung cancer.

[14]  T. Nishimura,et al.  Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes , 2017, Gastric Cancer.

[15]  T. Nakajima,et al.  Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody , 2016, Investigational New Drugs.

[16]  H. Yasui,et al.  Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer , 2016, Cancer Chemotherapy and Pharmacology.

[17]  T. Choueiri,et al.  Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. , 2015, European journal of cancer.

[18]  L. Emens,et al.  The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.

[19]  J. Sosman,et al.  Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy , 2013, Cancer Immunology Research.

[20]  J. Wolchok,et al.  Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.

[21]  N. Boku,et al.  Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. , 2012, Japanese journal of clinical oncology.

[22]  J. Harding,et al.  Vemurafenib sensitivity skin reaction after ipilimumab. , 2012, The New England journal of medicine.

[23]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Yixiang Wang,et al.  Activated CD4+ T Cells Dramatically Enhance Chemotherapeutic Tumor Responses In Vitro and In Vivo , 2009, The Journal of Immunology.

[25]  Masahiro Takeuchi,et al.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.

[26]  J. Heo,et al.  Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  A. Norman,et al.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  U. Haglund,et al.  Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  S. Pyrhönen,et al.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. , 1995, British Journal of Cancer.

[30]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.